Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients: a Randomized, Double-blind, Placebo-controlled Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Change from baseline in 'Eczema area and severity index (EASI)'
研究概览
简要总结
Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis. We aim to establish basic clinical efficacy and safety data for Jaungo in patients with Atopic Dermatitis.
详细描述
This study is a randomised, double blind, placebo-controlled, single-centre trial with three parallel arms (trial group 1, trial group 2, and control group). The diagnosis of Atopic Dermatitis will be made according to the criteria of Hanifin and Rajka. Participants will receive Jaungo or a placebo-drug for three weeks. Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks. Each participant will be examined for EASI (Eczema area and severity index), SCORAD (SCORing of Atopic Dermatitis), TEWL (Transepidermal water loss) and DLQI (Dermatology Life Quality Index) before and after applying medication. The outcomes to evaluate the maintenance of safety are Draize score, blood test and expert's opinion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 5 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The diagnosis of AD will be made according to the criteria of Hanifin and Rajka
- •Age: 5 years to 65 years
- •objective SCORAD ≦40, Diagnosis of Mild to Moderate Atopic Dermatitis (AD)
- •Exoriation≥1, Lichenification≥1, Dryness≥1 or Exoriation+Lichenification+Dryness≥3
- •Participants who able to express intention
- •Participants willing to provide written informed consent
排除标准
- •Participants have oozing in the lesion
- •Users of following medications prior to trial periods
- •① Oral steroids, immunosuppressants and antibiotics within 4 weeks prior to this trial
- •② Topical steroids, immunosuppressants and antibiotics within 2 weeks prior to this trial
- •③ Light therapy within 2 weeks prior to this trial
- •④ Other medications thought to be inappropriate by researchers
- •Participants have severe burn or wide wound
- •Participants have oozing or ulcer in the lesion
- •Allergic reactions to Angelica gigas, Siebold et Zuccarini, sesame oil and lard
- •Participants have skin disease except atopic dermatitis
- •Participants have severe renal function disease (sCr > 2.0 mg/dL)
- •Participants have severe liver function disease (ALT, AST, ALP ≥ 2.5 × normal limits)
- •Participants have uncontrolled chronic diseases
- •Pregnancy, lactation
- •Participation in another clinical trial within one month of enrolment
- •Underlying disease or history of severe disease, abnormal state (paralysis; mental retardation other emotional or mental problems; diseases that can affect the absorption of drugs; no enough time to participate in this trial; visual disturbance and hearing impairment; inability to understand written consent or engage in this study)
- •Judgment by experts that the potential subject's participation is inappropriate.
研究组 & 干预措施
trial group 1
Participants will receive Jaungo and placebo once a day for three weeks.
干预措施: Jaungo (Drug)
trial group 1
Participants will receive Jaungo and placebo once a day for three weeks.
干预措施: Placebo (Drug)
trial group 2
Participants will receive Jaungo twice a day for three weeks.
干预措施: Jaungo (Drug)
control group
Participants will receive placebo twice a day for three weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in 'Eczema area and severity index (EASI)'
时间窗: Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2)
次要结局
- Change from baseline in 'SCORing of Atopic Dermatitis (SCORAD)'(Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2))
- Change from baseline in 'Transepidermal water loss (TEWL)'(Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2))
- Change from baseline in 'Dermatology Life Quality Index (DLQI)'(Visit2(scheduled within a week of baseline), Visit3(in 3 weeks after visit2))
- Change from baseline in 'Total IgE'(Visit1, Visit3(in 3 weeks after visit2))
- The clinical phenotype evaluation system of atopic dermatitis(Visit2(scheduled within a week of baseline))
- Change from baseline in 'eosinophil count'(Visit1, Visit3(in 3 weeks after visit2))
- Change from baseline in 'IL-17'(Visit1, Visit3(in 3 weeks after visit2))
- Change from baseline in 'IL-22'(Visit1, Visit3(in 3 weeks after visit2))
- Change from baseline in 'IFN-γ'(Visit1, Visit3(in 3 weeks after visit2))
研究者
In-Hwa Choi
Clinical Professor
Kyung Hee University Hospital at Gangdong